Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.
Br J Clin Pharmacol
; 85(6): 1169-1179, 2019 06.
Article
en En
| MEDLINE
| ID: mdl-30471134
ABSTRACT
Fibrous dysplasia (FD) is a genetic, noninheritable rare bone disease caused by a postzygotic activating mutation of the α subunit of the stimulatory G-protein causing increased abnormal bone formation leading to pain, deformity and fractures. To date, no cure has been identified for FD/McCune-Albright syndrome (MAS) and treatment is symptomatic and aimed at decreasing pain and/or local bone turnover. Various drugs have been used to achieve clinical improvement in FD/MAS patients including bisphosphonates and denosumab, however further translational studies are also warranted to address unresolved pathophysiological issues and explore novel pharmacological targets for the management of FD/MAS. In this article, we review literature on the medical treatment of FD/MAS, discuss the unresolved pathophysiological issues and explore novel pharmacological targets for the management of FD/MAS.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Huesos
/
Remodelación Ósea
/
Conservadores de la Densidad Ósea
/
Displasia Fibrosa Ósea
Límite:
Animals
/
Humans
Idioma:
En
Año:
2019
Tipo del documento:
Article